Characterization of potential mechanisms of MYC-driven immune evasion in HNSCC could lead to the development of biomarker-selected targeted combinatorial therapeutic strategies to overcome resistance to immunotherapy. This evidence concerns the gene MYC and head and neck squamous cell carcinoma.